Chinanews.com, March 24. According to comprehensive Korean media reports, from the past 23 to 24, at 0:00, the number of new deaths in South Korea in a single day was 470, reaching the highest level since the outbreak of the epidemic.
At the same time, the new crown oral drug "Lagevrio" capsule developed by Merck & Co. of the United States has obtained emergency use authorization in South Korea, and will supply 20,000 copies in the first batch from the 26th of this month.
According to the report of the Central Epidemic Prevention and Control Headquarters of South Korea on the 24th, as of 0:00 that day, there were 395,598 new confirmed cases of the new crown in South Korea compared with the previous day, with a total of 10,822,836 confirmed cases.
There were 470 new deaths in a single day, the highest level since the outbreak began.
The Korea Food and Drug Safety Administration said on the 23rd local time that it has decided to approve the emergency use authorization of the new crown oral drug "Lagevrio" capsules developed by Merck & Co. of the United States and imported by South Korea's MSD.
This is the second new crown oral drug approved for use in South Korea after Pfizer's "Paxlovid" in December last year.
"Lagevrio" capsules will be used for treatment of patients who cannot take "Paxlovid", such as those who cannot use injectable therapeutic drugs, have severe liver dysfunction, etc.
The "Lagevrio" capsules are ribonucleic acid (RNA) analogs that can enter the virus as it replicates, leading it to self-destruct.
The capsules are to be taken for five days and should be administered as soon as possible within five days of being diagnosed and experiencing symptoms.
The South Korean government plans to introduce the first batch of 20,000 medicines. It is expected that the customs clearance process will be completed on the 24th, and it will be put into the first-line treatment from the 26th.